[HTML][HTML] ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
…, PN Tonin, D Provencher, D Miller… - … England Journal of …, 2010 - Mass Medical Soc
Background Ovarian clear-cell and endometrioid carcinomas may arise from endometriosis,
but the molecular events involved in this transformation have not been described. Methods …
but the molecular events involved in this transformation have not been described. Methods …
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies
…, DN Ionescu, A Rajput, LM Prentice, D Miller… - PLoS …, 2008 - journals.plos.org
Background Although it has long been appreciated that ovarian carcinoma subtypes (serous,
clear cell, endometrioid, and mucinous) are associated with different natural histories, most …
clear cell, endometrioid, and mucinous) are associated with different natural histories, most …
[HTML][HTML] Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary
…, R Varhol, KD Swenerton, D Miller… - … England Journal of …, 2009 - Mass Medical Soc
Background Granulosa-cell tumors (GCTs) are the most common type of malignant ovarian
sex cord–stromal tumor (SCST). The pathogenesis of these tumors is unknown. Moreover, …
sex cord–stromal tumor (SCST). The pathogenesis of these tumors is unknown. Moreover, …
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial
…, JM Langley, JA Bettinger, J Singer, D Money, D Miller… - Jama, 2013 - jamanetwork.com
Importance Global use of human papillomavirus (HPV) vaccines to prevent cervical cancer
is impeded by cost. A 2-dose schedule for girls may be possible. Objective To determine …
is impeded by cost. A 2-dose schedule for girls may be possible. Objective To determine …
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
…, KA Blood, M Smith, PT Spellman, Y Wang, DM Miller… - BMC cancer, 2008 - Springer
Background Subclassification of ovarian carcinomas can be used to guide treatment and
determine prognosis. Germline and somatic mutations, loss of heterozygosity (LOH), and …
determine prognosis. Germline and somatic mutations, loss of heterozygosity (LOH), and …
Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention
…, SJ Finlayson, DG Huntsman, DM Miller… - American journal of …, 2014 - Elsevier
Objective The purpose of this study was to assess the uptake and perioperative safety of
bilateral salpingectomy (BS) as an ovarian cancer risk-reduction strategy in low-risk women …
bilateral salpingectomy (BS) as an ovarian cancer risk-reduction strategy in low-risk women …
A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer
…, J Kwon, J McAlpine, G Stuart, S Thomson, D Miller - Gynecologic …, 2012 - Elsevier
GOAL: The goal of this study was to evaluate a mindfulness-based cognitive behavioral
intervention for sexual dysfunction in gynecologic cancer survivors compared to a wait-list …
intervention for sexual dysfunction in gynecologic cancer survivors compared to a wait-list …
The fallopian tube: primary site of most pelvic high-grade serous carcinomas
…, M Köbel, D Huntsman, B Rosen, D Miller - International Journal of …, 2009 - ijgc.bmj.com
Epithelial ovarian cancer is the most common cause of mortality from gynecologic malignancy,
and most of epithelial cancers are of serous type. The site of origin of pelvic high-grade …
and most of epithelial cancers are of serous type. The site of origin of pelvic high-grade …
HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy
…, KD Swenerton, DG Huntsman, CB Gilks, DM Miller - BMC cancer, 2009 - Springer
Background The response rate of ovarian mucinous carcinomas to paclitaxel/carboplatin is
low, prompting interest in targeted molecular therapies. We investigated HER2 expression …
low, prompting interest in targeted molecular therapies. We investigated HER2 expression …
Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies
…, JA Doherty, A Felberg, D Miller… - International journal …, 2013 - academic.oup.com
Background Tubal ligation is a protective factor for ovarian cancer, but it is unknown whether
this protection extends to all invasive histological subtypes or borderline tumors. We …
this protection extends to all invasive histological subtypes or borderline tumors. We …